Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 1/20 | 0.37 |
| ▸ | ADSS2 | P30520 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071493 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14928703 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14945963 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15249232 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL17263511 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL20126561 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15248821 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14946187 | 0.90 | P2RY2 (0.37) | RNASEL | |
| SCHEMBL15071506 | 0.81 | PGD (0.31) | TK1 | |
| SCHEMBL15248823 | 0.81 | PGD (0.31) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | MODERNATX, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140343129-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | RNASEL 61/4885ADSS2 317/4885TK1 198/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | RNASEL 61/4885ADSS2 317/4885TK1 198/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | RNASEL 61/4885ADSS2 561/4885TK1 402/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | RNASEL 35/4885ADSS2 400/4885TK1 535/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | RNASEL 98/4885ADSS2 1246/4885TK1 1197/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | RNASEL 98/4885ADSS2 1246/4885TK1 1197/4885 |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | POLRMT, RNMT, RNGTT | RNASEL 24/4885ADSS2 805/4885TK1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.